Consensus Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 28/08/2026 +03			5-day change	1st Jan Change
26.08 ^USD	-2.76%		+0.27%	+47.85%

08-28	Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up 2% for Week	MT
08-26	Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%	MT

Evolution of the Average Target: Zai Lab Limited

Evolution of the Target Price: Zai Lab Limited

Changes in Analyst Recommendations: Zai Lab Limited

d0.oQsuPT6pCzJtGlHg5aYOm-lPxGn_s4jD2jowdSutsfM.6GJ7VFfDPWRYWxWlkMNN970A8RmeysKWvndKRh74_N7GJkplUppEXll1ZQ~b65328052196a656ea05c830c65a98ce

Analysts' recommendations: Zai Lab Limited

01-07	UBS Initiates Zai Lab at Buy With $35 Price Target	MT
11-05	Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	RE
11-05	Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	CI
13/03/25	JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating	MT
03/03/25	BofA Securities Downgrades Zai Lab to Neutral	MT
12/07/24	JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating	MT
14/12/23	Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target	MT
26/10/23	Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating	MT
26/10/23	Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating	MT
10/08/23	Cantor Fitzgerald Initiates Coverage on Zai Lab With Overweight Rating, $70 Price Target	MT
12/06/23	BofA Adjusts Price Target on Zai Lab to $62.50 From $75, Maintains Buy Rating	MT
11/05/23	Citigroup Adjusts Price Target on Zai Lab to $130 From $138, Keeps Buy Rating	MT
16/03/23	JPMorgan Adjusts Price Target on Zai Lab to $70 From $79, Maintains Overweight Rating	MT
18/11/22	JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating	MT
11/11/22	Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating	MT
09/08/22	Citigroup Adjusts Zai Lab's Price Target to $199 From $193, Reiterates Buy Rating	MT
26/05/22	CSPC Pharma Shares Fall After Weaker 1Q Profit	DJ
12/05/22	Citigroup Adjusts Zai Lab Price Target to $193 From $198, Maintains Buy Rating	MT
11/05/22	SVB Securities Adjusts Zai Lab Price Target to $95 From $101, Maintains Outperform Rating	MT
06/05/22	Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating	MT
21/04/22	SVB Leerink Adjusts Zai Lab Price Target to $101 From $102, Maintains Outperform Rating	MT
04/04/22	JPMorgan Lowers Zai Lab's Price Target to $112 From $136, Maintains Overweight Rating	MT
03/03/22	Analyst recommendations: Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...
02/03/22	SVB Leerink Adjusts Zai Lab Price Target to $102 From $194, Maintains Outperform Rating	MT
04/12/21	Citigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ZAI LAB LIMITED					+27.07%
	REGENERON PHARMACEUTICALS, INC.					+5.82%
	CSL LIMITED					-5.25%
	MODERNA, INC.					-22.73%
	SAMSUNG BIOLOGICS CO.,LTD.					+32.94%
	UCB					+31.76%
	BIOGEN INC.					+8.11%
	INCYTE CORPORATION					+2.22%
	INNOVENT BIOLOGICS, INC.					+19.54%
	SWEDISH ORPHAN BIOVITRUM AB					+6.73%
	Average					+10.62%
	Weighted average by Cap.					+7.74%